Eli Lilly (LLY) news

Older LLY news events, each with the realized, point-in-time move the market made — page 2 of 8. Back to the LLY overview → · Full LLY reaction history →

Latest news

Recent LLY events, each with its measured reaction. (Page 2 of 8.)

DateHeadlineEventSource5-minTo close
Lilly launches "The Memory Radio Station" across Europe, inviting the public to visually reconstruct fading memories through GenAIPress releasePR Newswire+2.00%+7.03%
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapyPress releasePR Newswire+2.00%+7.03%
What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight managementPress releasePR Newswire-1.35%-0.45%
Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disordersPress releasePR Newswire-0.56%-1.56%
Form 11-K ELI LILLY & Co For: Dec 31SEC filing · Form 11-KSEC EDGAR+0.17%-0.02%
Lilly declares third-quarter 2026 dividendPress releasePR Newswire-0.25%+0.20%
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLLPress releasePR Newswire-1.68%-0.41%
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual MeetingPress releasePR Newswire-1.68%-0.41%
Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatablePress releasePR Newswire-0.29%-1.25%
Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non-communicable Disease and Chronic ConditionsPress releaseBusiness Wire+0.12%-1.57%
FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitisPress releasePR Newswire-0.29%-1.25%
Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trialsPress releasePR Newswire-0.16%-0.81%
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopausePress releasePR Newswire-0.03%-0.81%
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complicationsPress releasePR Newswire-0.03%-0.81%
Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual MeetingPress releasePR Newswire+0.98%-0.15%
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancerPress releasePR Newswire-0.93%-1.64%
Foundayo and Zepbound now covered for millions of AmericansPress releasePR Newswire+0.93%+2.62%
Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity carePress releasePR Newswire-0.15%+0.04%
Lilly to participate in Goldman Sachs 47th Annual Global Healthcare ConferencePress releasePR Newswire-0.14%-0.46%
Lilly announces three acquisitions to build infectious disease portfolioPress releasePR Newswire-0.20%-1.00%
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemiaPress releasePR Newswire-0.20%-1.00%
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual MeetingPress releasePR Newswire+0.80%+1.43%
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trialPress releasePR Newswire-0.02%+1.43%
Form 8-K ELI LILLY & Co For: May 20SEC filing · Form 8-KSEC EDGAR-0.02%+1.43%
Lilly to participate in Bernstein's 42nd Annual Strategic Decisions ConferencePress releasePR Newswire-0.31%-0.58%
Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youthPress releasePR Newswire-1.27%-1.25%
Lilly and UNICEF collaborate to give millions of children a healthier startPress releasePR Newswire-1.13%-1.06%
In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantriesPress releasePR Newswire-0.26%-0.32%
Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trialsPress releasePR Newswire-0.16%+1.97%
Form SD ELI LILLY & CoSEC filing · Form SDSEC EDGAR+0.02%+1.52%
The Next Generation of the GLP-1 Revolution Is Already UnderwayPress releaseGlobeNewswire+2.16%+2.34%
Form 8-K ELI LILLY & Co For: May 04SEC filing · Form 8-KSEC EDGAR-0.07%-2.63%
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facilityPress releasePR Newswire-0.53%-0.43%
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four yearsPress releasePR Newswire-0.28%+1.74%
HEALTH CANADA AUTHORIZES LILLY'S KISUNLA™ (DONANEMAB), A NEW TREATMENT FOR EARLY ALZHEIMER'S DISEASEPress releaseCanada Newswire+0.90%+0.94%
Lilly declares second-quarter 2026 dividendPress releasePR Newswire-0.00%+0.76%
PDA Releases Revised Technical Reports on Process Validation and Biologics Reprocessing to Support Manufacturing ExcellencePress releasePR Web+0.90%+0.94%
Form 10-Q ELI LILLY & Co For: Mar 31SEC filing · Form 10-QSEC EDGAR+0.01%+1.36%
Form 8-K ELI LILLY & Co For: Apr 30SEC filing · Form 8-KSEC EDGAR+0.60%+3.84%
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicinesPress releasePR Newswire+0.60%+3.84%
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia veraPress releasePR Newswire+0.98%-0.77%
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation TrialPress releaseGlobeNewswire-0.25%-1.06%
Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapiesPress releasePR Newswire-0.06%-0.66%
ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic healthPress releasePR Newswire+0.55%-0.66%
Lilly confirms date and conference call for first-quarter 2026 financial results announcementPress releasePR Newswire-0.15%-1.11%
Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLLPress releasePR Newswire-0.52%-0.90%
Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.Press releasePR Newswire+0.23%+0.91%
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictionsPress releasePR Newswire-0.24%-0.43%
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disordersPress releasePR Newswire+1.93%+2.94%
Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesityPress releasePR Newswire+0.18%-0.07%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground